PHARMACOLOGICAL CORRECTION OF ADMA-ENOS-ASSOCIATED TARGETS IN PREECLAMPSIA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Methylated L-arginine analogues, such as asymmetric dimetylarginine (ADMA) and monomethylarginine (L-NMMA), are endogenous inhibitors of endothelial nitric oxide (e-NOS). It has been recently established that the maternal plasma concentrations of ADMA are higher in women with preeclampsia and the elevated ADMA concentrations are a predictor of preeclampsia. The previously presented studies showed that L-arginine on an ADMA-like model of L-NAME-induced endothelial dysfunction was effective in increasing the activity of endothelial NO synthase and the generation of nitric oxide. The eNOS activator resveratrol, antioxidants, potentiated polyclonal antibodies against eNOS, etc. were effective on this model. Investigations of endothelium-protective activity have been under way on other ADMA-eNOS-associated experimental models of metabolic syndrome X, homocysteine-, hypoestrogenism-, and sepsis-induced endothelial dysfunction and endothelial dysfunction in reactive postvaccination vasculitis.

Full Text

Restricted Access

About the authors

M. V POKROVSKY

Kursk State Medical lniversity

Email: mvpokrovskiy@pharmstd.ru

T. G POKROVSKAYA

Kursk State Medical lniversity

V. V GUREYEV

Kursk State Medical lniversity

A. A BARSUK

Kursk State Medical lniversity

E. V PROSKURYAKOVA

Kursk State Medical lniversity

M. V KOROKIN

Kursk State Medical lniversity

A. S BELOUS

Kursk State Medical lniversity

L. V KOROKINA

Kursk State Medical lniversity

V. A RAGULINA

Kursk State Medical lniversity

O. S GUDYREV

Belgorod State University

O. V LEVASHOVA

Kursk State Medical lniversity

A. E KOROLEV

Kursk State Medical lniversity

N. V MALTSEVA

Kursk State Medical lniversity

O. S POLYANSKAYA

Kursk State Medical lniversity

E. G TEREKHOVA

Kursk State Medical lniversity

A. V BABKO

Kursk State Medical lniversity

O. O NOVIKOV

Belgorod State University

E. T ZHILYAKOVA

Belgorod State University

V. N SOROKOPUDOV

Belgorod State University

I. M KOLESNIK

Kursk State Medical lniversity

References

  1. Артюшкова Е.Б., Покровский М.В., Кочкаров В.И. и др. Новый взгляд на коррекцию эндотелиальной дисфункции // Rus. J. Immunol. — 2006. — Vol. 9, suppl. 3. — P. 59—63.
  2. Артюшкова Е.Б., Пашков Д.В., Покровский М.В. и др. Возможности фармакологической коррекции хронической ишемии конечности в эксперименте // Экспер. и клин. фармакол. — 2008. — Т. 71, № 3. — С. 23—25.
  3. Артюшкова Е.Б., Покровский М.В., Покровская Т.Г. и др. Эндотелиопротективные эффекты L-аргинина при экспериментальном моделировании дефицита оксида азота // Экспер. и клин. фармакол. — 2008. — Т. 71, № 2. — С. 29—31.
  4. Покровский М.В., Кочкаров В.И., Покровская Т.Г. и др. Методические подходы для количественной оценки развития эндотелиальной дисфункции при L-NAME-индуцированной модели дефицита оксида азота в эксперименте // Кубанск. науч. мед. вестн. — 2006. — № 10 (91). — С. 72—77.
  5. Покровский М.В., Кочкаров В.И., Покровская Т.Г. и др. Сравнительное изучение потенциальных эндотелийпротекторов и препарата Импаза при моделировании дефицита оксида азота // Бюл. экспер. биол. — 2009. — Т. 148, № 8, прил. — С. 154—158.
  6. Ariza A.C. Endothelin 1 and angiotensin II in preeclampsia // Rev. Invest. Clin. — 2007. — Vol. 59, № 1. — P. 48—56.
  7. Bayhan G. Potential atherogenic roles of lipids, lipoprotein(a) and lipid peroxidation in preeclampsia // Gynecol. Endocrinol. — 2005. — Vol. 21, № 1. — P. 1—6.
  8. Böger R.H. The role of nitric oxide synthase inhibition by asymmetric dimethylarginine in the pathophysiology of preeclampsia // Gynecol. Obstet. Invest. — 2009. — Vol. 69, № 1. — P. 1—13.
  9. Fliser D. Asymmetric dimethylarginine (ADMA): the silent transition from an «uraemic toxin» to a global cardiovascular risk molecule // Eur. J. Clin. Invest. — 2005. — Vol. 35, № 2. — P. 71—79.
  10. Grill S. Potential markers of preeclampsia — a review // Reprod. Biol. Endocrinol. — 2009. — Vol. 14, № 7. — P. 70.
  11. Herr F. Studies of placental vasculogenesis: a way to understand pregnancy pathology? // Z. Geburtsh. Neonat. — 2009. — Bd. 213, № 3. — S. 96—100.
  12. Kontic-Vucinic O., Terzic М., Radunovic N. The role of antioxidant vitamins in hypertensive disorders of pregnancy // J. Perinat. Med. — 2008. — Vol. 36, № 4. — P. 282—290.
  13. LaMarca B. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha // Hypertension. — 2005. — Vol. 46. — P. 1022—1025.
  14. LaMarca B. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin // Hypertension. — 2009. — Vol. 54, № 4. — P. 905—909.
  15. Ohkuchi A. Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria // Hypertens. Pregnancy. — 2009. — Vol. 28, № 1. — P. 95-108.
  16. Perticone F. Endothelial dysfunction, ADMA and insulin resistance in essential hypertension // Int. J. Cardiol. — 2009. — Vol. 23, № 1. — P. 113—123.
  17. Pope A.J., Karuppiah K., Cardounel A.J. Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production // Pharmacol. Res. — 2009. — Vol. 60, № 6. — P. 461—465.
  18. Powers R. Moderate hyperhomocysteinemia decreases endothelial-dependent vasorelaxation in pregnant but not nonpregnant mice // Hypertension. — 2004. — Vol. 44. — P. 327—333.
  19. Roberts J.M. Preeclampsia more than 1 disease: or is it? // Hypertension. — 2008. — Vol. 51, № 4. — P. 1231—1238.
  20. Roberts L. Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine // Hypertension. — 2006. — Vol. 47. — P. 615—618.
  21. Savvidou M.D. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop preeclampsia // Lancet. — 2003. — Vol. 361. — P. 1511—1517.
  22. Shah D.M. Role of the renin-angiotensin system in the pathogenesis of preeclampsia // Am. J. Renal Physiol. — 2005. — Vol. 288. — P. F614—F625.
  23. Smith C.L. Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype // Biochem. Biophys. Res. Commun. — 2003. — Vol. 308. — P. 984—989.
  24. Speer P.D. Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infants // Am. J. Obstet. Gynecol. — 2008. — Vol. 198, № 1. — P. 112—117.
  25. Torrens C. Folate supplementation during pregnancy improves offspring cardiovascular dysfunction induced by protein restriction // Hypertension. — 2006. — Vol. 47. — P. 982—987.
  26. Vladimirova-Kitova L. Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia // Clin. Physiol. Funct. Imag. — 2008. — Vol. 28, № 6. — P. 417—425.
  27. Wang A. Preeclampsia: the role of angiogenic factors in its pathogenesis // Physiology (Bethesda). — 2009. — Vol. 24, № 1. — P. 147—158.
  28. Wang Y. Digibind attenuates cytokine TNFalpha-induced endothelial inflammatory response: potential benefit role of digibind in preeclampsia // J. Perinatol. — 2009. — Vol. 29, № 3. — P. 195—200.
  29. Xia Y. Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia // Hypertension. — 2007. — Vol. 50. — P. 269—275.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies